Detalles de la búsqueda
1.
Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
Mod Rheumatol
; 33(1): 122-133, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34915574
2.
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Mod Rheumatol
; 33(4): 751-757, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208293
3.
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
RMD Open
; 8(1)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35428697
4.
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Arthritis Res Ther
; 24(1): 46, 2022 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172878
5.
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Clin J Am Soc Nephrol
; 17(11): 1620-1630, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302567
6.
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
Eur Heart J
; 31(7): 824-31, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20118174
7.
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
RMD Open
; 7(2)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215703
8.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet
; 373(9681): 2125-35, 2009 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19501900
9.
Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
Pulm Circ
; 9(2): 2045894019846433, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30957635
10.
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Cardiovasc Diabetol
; 7: 10, 2008 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-18435852
11.
Sample size estimation for non-inferiority trials of time-to-event data.
Pharm Stat
; 7(4): 236-44, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-17583558
12.
Cancer and bone fractures in observational follow-up of the RECORD study.
Acta Diabetol
; 52(3): 539-46, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524432
13.
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.
Diabetes Care
; 34(6): 1394-6, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21562320
Resultados
1 -
13
de 13
1
Próxima >
>>